Supreme Court Report

Supreme Court of the United States · Official docket →

Apotex Inc., et al. v. Cephalon, Inc., et al.

Paid petition · United States Court of Appeals for the Federal Circuit, No. 2020-2134, 2020-2137 · judgment August 13, 2021


Certiorari denied · February 22, 2022
Pre-decision estimate: 1% cert probability

Before the decision, well below the 4.1% base rate, with no standout signals pointing toward a grant.

Question presented

Whether claimed inventions involving reformulating and administering an old drug in ways that are no better than prior techniques, and which had been taught and suggested in the prior art, are nevertheless patentable although these formulations and methods were at least “obvious to try” under this Court’s decision in KSR, Int’l v. Teleflex, Inc., merely because the court found that a person of ordinary skill in the art would not have been sufficiently motivated to make and administer the drug in this way.

Counsel of record

For petitioner
Steven Eric Feldman
Hahn Loeser and Parks LLP

For respondent

Case

Conference history
Distributed for 1 conference

Proceedings

  1. Feb 22 2022
    Petition DENIED.
  2. Feb 02 2022
    DISTRIBUTED for Conference of 2/18/2022.
  3. Dec 14 2021
    Petition for a writ of certiorari filed. (Response due January 18, 2022)